![](/img/cover-not-exists.png)
Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
Kosmidis, Michalis L., Pikazis, Dimitris, Vlachoyiannopoulos, Panayotis, Tzioufas, Athanasios G., Dalakas, Marinos C.Volume:
6
Language:
english
Journal:
Neurology - Neuroimmunology Neuroinflammation
DOI:
10.1212/NXI.0000000000000581
Date:
July, 2019
File:
PDF, 311 KB
english, 2019